Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photoprotection activity evaluation of a hesperetin nanocapsule formulation
RBR-4w44wkdPhase 1Completed
- Sponsor
- Universidade Federal de Sergipe
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, double-blind trial of hesperetin and titanium dioxide in cutaneous malignancy (4 arms), sponsored by Universidade Federal de Sergipe. Primary endpoints: Erythema, Melanin and 1 more. Started Oct 2024; status: completed.
02
Drugs
hesperetintitanium dioxide
03
Conditions
cutaneous malignancy
Beyond the preview
Go deeper on RBR-4w44wkd.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4w44wkd.